FDA
-
-
-
-
-
-
-
Bioventus Receives FDA 510(k) Clearances for two Next-Generation Peripheral Nerve Stimulation Products
-
-
-
-
-
-
-
Bioventus Reports First Quarter Financial Results
-
-
-
-
-
-
-
Bioventus Reports Fourth Quarter and Full-Year 2022 Financial Results
-
-
-
-
-
-
-
Bioventus Reports Third Quarter Results; Updates Full-Year 2022 Financial Guidance
-
-
-
-
-
-
-
Bioventus Announces Preliminary First Quarter Net Sales and Adjusted EBITDA
-
-
-
-
-
-
-
Bioventus (BVS) Appoints Mark Singleton as CFO
-
-
-
-
-
-
-
Bioventus Receives US FDA Clearance for BoneScalpel® Access™
-
322,243 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

